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ABSTRACT 
Modulation of Transforming Growth Factor β-induced Endothelial-Mesenchymal Transition by 
Nck 
 
 
Thuy Tien Tran 
Department of Veterinary Medicine  
Texas A&M University 
 
 
Research Advisor: Dr. Gonzalo Rivera 
Department of Veterinary Pathology 
Texas A&M University 
 
 
 Fibrotic disorders, including atherosclerosis, are known to concur with endothelial-to-
mesenchymal transition (EndMT) induced by cues from the tissue microenvironment such as 
transforming growth factor β (TGF-β). Nck, a family of adaptor proteins linking tyrosine 
phosphorylation with cytoskeletal remodeling, is involved in cardiovascular morphogenesis. 
Although EndMT underlies cardiovascular development, a potential role for Nck in TGF-β-
induced EndMT is yet to be determined. To address this gap in the knowledge, naïve human 
umbilical vein endothelial cells (HUVEC) or HUVEC with short interference RNA (siRNA)-
mediated silencing of Nck were left untreated or treated with TGF-β2 for 48 hours. Expression 
levels of Nck, endothelial and mesenchymal cell markers were determined by western blotting. 
With the successful replications of TGF-β induced EndMT, the results from silencing Nck with 
the presence of TGF-β presented the downregulation of both EC, CD31 and VE-Cad, and MC, 
vimentin, specific markers. The results suggest that Nck plays a critical role in TGF-β induced 
EndMT, while also provide a guide for future research of the signaling mechanisms modulated 
by Nck in TGF-β-stimulated cells.   
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NOMENCLATURE 
 
BSA Bovine Serum Albumin  
CM  Complete media  
EndMT Endothelial-to-mesenchymal transition 
HUVEC Human umbilical vein endothelial cells  
Nck  Non-catalytic region of tyrosine kinase   
NFDM Non-Fat Dried Milk  
pSmad2/3 phospho-Smad2/3 
siRNA short interference RNA  
TGF-β2 Transforming growth factor-beta 2 
VE-Cad VE-Cadherin 
αSMA  Alpha-smooth muscle actin 
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CHAPTER I 
INTRODUCTION 
 
Endothelial cells form a thin layer lining the lumen of blood vessels to regulate the 
movement of fluid, nutrients, and gases in and out of tissues (Aman et al., 2016). The 
endothelium regulates blood flow and contributes to tissue homeostasis. Depending on external 
signals, it may favor antithrombotic or prothrombotic states (Yau et al., 2015). Under 
physiological conditions, the endothelium of mature blood vessels regulates permeability and 
tissue perfusion.  
EndMT is a physiological process that entail partial or full conversion of endothelial cells 
into mesenchymal cells. EndMT is required during cardiovascular formation. In adults, the 
occurrence of EndMT may contribute to pathologies involving vascular dysfunction and fibrosis 
(Dejana & Lampugnani, 2018). During EndMT, endothelial cells downregulate endothelial cell-
specific markers and begin to express markers typical of mesenchymal cells (Figure 1). In 
addition, cells undergoing EndMT remodel their cytoskeletal organization, cell-cell junctions, 
and acquired increased motility (Cho et al., 2018). Characteristic endothelial markers are 
represented by proteins such as CD31 and vascular endothelial cadherin (VE-cadherin) whereas 
typical mesenchymal markers include, among others, alpha-smooth muscle actin (αSMA) and 
vimentin. EndMT contributes to a pro-thrombotic state and is linked to increased vascular 
permeability control and the release of growth factors (Dejana & Lampugnani, 2018). EndMT is 
also a process contributing to fibrotic diseases, including atherosclerosis. The current 
understanding is that EndMT represents a continuum of intermediate cellular stages between 
fully differentiated endothelial and mesenchymal phenotypes (Schwartz et al., 2018). It is 
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hypothesized that EndMT may represent an attempt of endothelial cells to regain homeostasis 
following vascular damage. 
It is well known that TGF-β is a key driver of EndMT. TGF-β is a family of cytokines 
capable of activating SMAD-dependent (canonical) as well as Rho-A-dependent (non-canonical) 
pathways downstream of TGF-β receptor stimulation (Heldin & Moustakas, 2016). TGF-β has 
been shown to induce EndMT through activation of SMAD proteins (Figure 2). Although 
induction of EndMT by TGF-β is well documented, how Nck modulates TGF-stimulated EndMT 
remains unknown. The Nck family are adaptors proteins that regulate cell adhesion and 
cytoskeletal remodeling during cardiovascular morphogenesis (Clouthier et al., 2015). There are 
two paralogues in the Nck family; Nck1/Nckα and Nck2/Nckβ. Nck adaptors consists of three 
SH3 domains followed by one C-terminal SH2 domain, thus they facilitate the formation of 
signaling complexes in response to activation of tyrosine phosphorylation (Lettau et al., 2009).  
This investigation addresses the role of Nck in TGF-β-induced EndMT. To this end, we 
combined culture of human umbilical vein endothelial cells (HUVEC), molecular genetics, and 
assessment of endothelial/mesenchymal marker expression by western blotting. 
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Figure 1. TGF-β induces EndMT. Endothelial cells experience EndMT in response to TGF-β 
signaling activation. As cells lose endothelial-specific and gain mesenchymal markers, the 
organization of the endothelium is disrupted and vessel permeability is increased.  
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Figure 2. TGF-β signaling pathway.  TGF-β is part of the cytokine family that promotes 
EndMT in endothelial cells. TGF-β activates the phosphorylation of Smad2/3 that will regulate 
gene expression. The binding of pSmad2/3 to DNA will enhance the expression of mesenchymal 
markers such as SM22α, Vimentin, and αSMA. In turn, the expression of endothelial markers, 
such as CD31 and VE-Cadherin, is downregulated. 
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CHAPTER II 
METHODS 
 
Cell culture  
Frozen HUVEC cells were thawed at 37°C in a heated water bath and plated on a 
fibronectin-coated 10cm plate in complete media with 2% serum. Cells were then incubated at 
37°C with 5% CO2. Media was changed the next day and then every 48 hours until 90% 
confluence. Regents used are listed in Appendix A. 
 
TGF-β stimulation 
HUVEC cells were plated at a density of 15 x 104cells/cm2 onto fibronectin-coated 6-well 
plates in complete media. After 24 hours, cells were either left untreated or treated with 10ng/mL 
of TGF-β2 in 0.2% serum starvation media (Figure 3). The media was changed every 24 hours 
until 48 hours (Table 1). Regents used are listed in Appendix A.  
 
Figure 3. Experimental design using 6-well plates for TGF-β2 treatment. In one 6-well plate, 
3 wells were left untreated as a control, and 3 wells were treated with 10 ng/mL TGF-β2 every 
24 hours.  
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Table 1. Timeline of protocols performed for 48 hour treatment of TGF-β. 
Time 
Interval 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
48 hours 
Plate cells 
onto 10cm 
plate 
Change 
media 
(CM) 
Pass cells 
onto 6-well 
plates 
Add TGF-
β2 to half 
of wells 
Add TGF-
β2 to half 
of wells 
Collect cell 
lysate  
 
siRNA knockdown  
HUVEC cells were passed at 20 x 104cells/cm2 onto fibronectin-coated 6-well plates in 
complete media. The media was then replaced with antibiotic-free media after 24 hours to begin 
the transfection treatment. Dilutions of siRNA and basal media were prepared by combining 
diluted siRNA buffer with diluted DharmaFECT (Table 2). The mixtures were added into each 
well and the cells were incubated with the siRNA at 37°C for 6 hours. The antibiotic-free 
complete media was then replaced with complete media. Cells were then collected after 24 hours 
and passed at 10 x 104cells/cm2 onto fibronectin-coated 6-well plates for TGF-β treatment (Table 
3).   
Table 2. Dilutions preparation of siRNA and antibiotic-free complete media.  
Plating 
Format 
Surface Area 
(cm2/well) 
Tube 1: diluted siRNA 
(µl/well) 
Tube 2: diluted DharmaFECT 
(µl/well) 
Volume of 
5uM siRNA 
(µl) 
Serum-free 
Medium (µl) 
Volume of 
DharamaFECT4 
reagent (µl) 
Basal 
Medium (µl) 
6-well plate 
siNck 
10 
Nck1: 20 
Nck2: 20 
160 4 196 
6-well plate 
siScr 
10 10 190 4 196 
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Table 3. Timeline of protocols performed for transfection followed by TGF-β treatment. 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
Plate 
cells onto 
10cm 
plate 
Change 
media 
(CM) 
Pass cells 
onto 6-
well 
plates  
siRNA 
transfection 
Pass cells 
onto 6-
well 
plates 
Add 
TGF-β2 
to half of 
wells  
Add 
TGF-β2 
to half of 
wells  
Collect 
cell 
lysate  
 
Western blot 
SDS-PAGE was used to separate the proteins based on their molecular weight. The 
proteins were transferred to a 0.2μm pore nitrocellulose membrane. The membrane was blocked 
with either nonfat dry milk or bovine serum albumin for one hour at room temperature, incubated 
at 4°C overnight with the primary antibody, and incubated with the secondary antibody for one 
hour at room temperature. The membrane was then imaged by chemiluminesence using an 
ImageQuant 4000. Western blots conditions are listed in Appendix B.   
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CHAPTER III 
RESULTS 
 
TGF-β2 induces EndMT in HUVEC  
 After treating HUVEC with TGF-β2 for 48 hours there was evidence that cells 
experienced EndMT. A change in cellular morphology was a major difference between the 
control and treatment group (Figure 4). For the control group, cells are tightly packed together 
and presented a cobblestone morphology (Fig. 1 A). As for the treatment group, cells were 
sparser and presented spindled shaped morphologies (Fig. 1 B). Cells extracts were obtained and 
analyzed to determine expression of endothelial and mesenchymal markers by western blotting. 
The western blot analysis shows that there was an upregulation of mesenchymal cell marker, 
vimentin, and downregulation of endothelial cell markers, VE-Cadherin and CD31, in response 
to TGF-β treatment (Figure 5). Total Smad2/3 and phospho-Smad2/3 (pSmad2/3) were used to 
determine TGF-β2 signaling activation (Figure 5). TGF-β2 induced EndMT is pSmad2/3 which 
is the indicator for TGF-β pathway activation. There is a more prominent signal in the treatment 
group for pSmad2/3 which suggests that TGF-β2 did cause the HUVEC to undergo EndMT.  
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Figure 4. TGF-β2 treatment alters cell morphology after 48 hours. The cell morphology after 
treating with 0.2% serum starvation media only (A), and 10ng/mL of TGF-β2 in 0.2% serum 
starvation media (B). 
 
 
Figure 5. TGF-β2 induces EndMT in HUVEC. Western blots analysis of HUVECs 48 hours 
control and treatment group. The endothelial cell markers, VE-Cadherin and CD31, presented a 
downregulation of signaling. The mesenchymal cell marker, Vimentin, presented an upregulation 
of signaling. Phosphorylated Smad2/3 was used as an indicator of TGF-β pathway activation. 
GAPDH was used a loading control.  
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Role of Nck in TGF-β2-induced EndMT 
 We performed protein silencing using non-targeting (siScr) or Nck-targeting (siNck) 
oligonucleotides. Based on the results, siNck reduced the expression of both endothelial cell 
markers, VE-Cadherin and CD31, and mesenchymal cell marker, Vimentin (Figure 6). When 
compared to siNck, the protein bands of the control and treatment group of siScr presented a less 
dramatic change. Basically, the change of protein expression for siNck was more intense than 
siScr, which presented a slight change of intensity. Intensities are indicated by the lightness and 
darkness of bands. For the siNck group, there was a downregulation of Nck when compared to 
the siScr group, which indicated the successful transfection of knocking down Nck from the 
DNA of the HUVEC cells. With the successful knockdown of Nck and the equal loading 
indicated from GAPDH, it can be inferred that silencing of Nck results in downregulation of both 
endothelial and mesenchymal cell markers.  
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Figure 6. siNck reduces effects of TGF-β induced EndMT. Western blot analysis comparing 
siScr and siNck. The endothelial cell markers, VE-Cadherin and CD31, presented a 
downregulation of signaling in both groups. The mesenchymal cell marker, Vimentin, presented 
an upregulation of signaling for siScr and a downregulation of signaling for siNck. Nck was an 
indicator for the effectiveness of siNck treatment. GAPDH was used a loading control.  
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CHAPTER IV 
CONCLUSION 
 
Effect of Nck adaptor proteins  
 The results demonstrate a significant reduction in the progression of EndMT in siNck 
HUVEC cells. There was a downregulation in both endothelial and mesenchymal cell markers 
for siNck, while siScr presented the normal progression of EndMT, which had a downregulation 
of endothelial cell markers and an upregulation of mesenchymal cell markers. These results 
suggest that Nck plays an important role in the progression of TGF-β induced EndMT.  
 
Future Research  
 From the studies of the role of Nck in TGF-β induced EndMT, future studies will revolve 
around the signaling mechanisms modulated by Nck in TGF-β-stimulated cells. In addition to 
finding the signaling mechanisms, time intervals, such as 48 or 96 hours, would be tested to see 
the effects of TGF-β on HUVEC cells. We hypothesize that the Nck family drives EndMT in 
response to activation of TGF-β signaling.  
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APPENDIX A 
REAGENTS  
 
Table 4. Reagents used to culture and harvest cells and perform Western blots  
Process Reagent Vendor Catalogue number 
Cell Culture and 
Passing 
EGM2 Bullet kit  
(EBM2 Basal Media + 
growth factors) 
Lonza CC-3162 
HUVEC Lonza CC-2519 
Trypsin/EDTA 
(0.25mg/mL) 
Lonza CC-5012 
FBS Gemini 100-106 
PBS Gibco 10010-031 
Fibronectin Calbiochem 341631-5MG 
Transfection  
5X siRNA buffer  Thermo Fisher 002000-UB-100 
DharmaFECT4 GE Dharmacon T2004-02 
ON-TARGETplus Nck1 
siRNA  
GE Dharmacon J-006354-06-0002 
ON-TARGETplus Nck2 
siRNA 
GE Dharmacon J-019547-05-0002 
ON-TARGETplus Non-
targeting Pool 
GE Dharmacon D-001810-10-05 
Harvesting Cells 
1M Tris, pH 7.4 Sigma T1503-1KG 
5M NaCl EMD SX0420-5 
0.5M EDTA  Sigma E5134 
Triton X-100 VWR 9002-93-1 
1M β-glycerophosphate Sigma G9422 
Glycerol J.T. Baker 4043-00 
0.5M 
phenylmethylsulfonyl 
fluoride in DMSO 
Sigma P-7626 
Aprotinin, from Bovine 
Lung 
Sigma A6279-5ML 
100mM Sodium 
Orthovanadate 
(Na3VO4) 
Alfa Aesar 81104 
Sodium Dodecyl 
Sulfate-
Polyacrylamide 
Gel 
Electrophoresis 
30% Acrylamide 
Solution 
Protogel EC890 
1M Tris, pH 8.8 
Sigma T1503-1KG 
1M Tris, pH 6.8 
10% Sodium dodecyl 
sulfate 
J.T. Baker 4095-02 
20 
(SDS-PAGE) Gel 
Casting 
10% Ammonium 
persulfate (APS) 
J.T. Baker 4030-04 
TEMED Thermo Scientific™ 17919 
Precast Gels  
NuPAGE™ 10% Bis-
Tris Protein Gels, 1.0 
mm, 10-well 
Novex™, NuPAGE® NP0301PK2 
NuPAGE™ MOPS SDS 
Running Buffer (20X) 
NuPAGE® NP0001 
NuPAGE™ Antioxidant NuPAGE® NP0005 
SDS-PAGE 
Protein Transfer 
to Nitrocellulose 
Nitrocellulose 
Membrane  
BioTraceTM NT 66485 
WhatmanTM 
Chromatography Paper 
WhatmanTM 3030-6188 
Detection of 
Western blot 
Signal 
Western Lightning Plus-
ECL, Enhanced 
Chemiluminescence 
Substrate 
PerkinElmer NEL103E001EA 
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APPENDIX B 
WESTERN BLOT CONDITIONS FOR ALL ANTIBODIES USED 
To block non-specific binding on the membrane, Non-Fat Dried Milk (NFDM) or Bovine Serum 
Albumin (BSA) were diluted in 1X Tris-Buffered Saline and Tween 20 (TBST). The membranes 
were blocked for one hour at room temperature on the Belly Dancer and placed in 1X TBST 
upon completion. The membranes were then incubated in the primary antibody overnight at 4°C 
on an orbital shaker and then washed 5 times for 5 minutes with TBST (Table 5). The secondary 
antibodies were incubated for an hour at room temperature on the Belly Dancer and washed with 
TBST 5 times for 5 minutes (Table 6). To detect signals, the Western Lightening Plus-ECL kit 
was used and the membranes were imaged by ImageQuant 4000. 
Table 5. Western blot conditions for primary antibodies used. 
Primary Antibody Blocking Solution 
Antibody 
Concentration 
Primary Dilution 
CD31 
3% NFDM 
1/4000 
3% NFDM 
GAPDH 1/5000 
Nck 1/4000 
VE-Cadherin 1/1000 
Vimentin 1/2000 
pSmad2/3 1/500 
5% BSA 
Smad2/3 3% BSA 1/1000 
Table 6. Western blot conditions for secondary antibodies used. 
Secondary Antibody 
Primary Antibodies 
Targeted 
Antibody 
Concentration 
Secondary Dilution 
Goat anti-Mouse IgG 
GAPDH 
1/1000 
3% NFDM 
Nck 
VE-Cadherin 
Vimentin 
Goat anti-Rabbit IgG 
CD31 
1/5000 Smad2/3 
pSmad2/3 
